ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1574132
Novel perceptions and insights into the rare hematologic malignancy of acute megakaryocytic leukemia: A multicenter clinical retrospective study
Provisionally accepted
Yuan Liu1
Yanquan Liu2
Xiaojun Chen3
Yue Yin4Zhenyuan Xu1Jiachen Xie1
Jianzhen Shen4He Huang1
Hui Dong Guo1*- 1First Affiliated Hospital of Gannan Medical University, Ganzhou, China
- 2First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong Province, China
- 3Affiliated Hospital of Putian University, Putian, Fujian Province, China
- 4Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Acute megakaryocytic leukemia (AMKL) constitutes a rare subtype of acute myeloid leukemia in clinical practice and exhibits a high degree of heterogeneity. This study endeavors to explore the clinical manifestations, diagnosis, treatment, and prognosis of AMKL, offering novel perspectives for both basic and clinical investigations of rare myeloid tumors in the fields of oncology and hematology.Methods: For details, please refer to the main body of the manuscript fileResults: For details, please refer to the main body of the manuscript fileConclusion: AMKL is infrequent in clinical practice, features a poor prognosis, lacks specificity in clinical manifestations, and is prone to misdiagnosis or omission. Clinical trials of new drugs should be prioritized, while close monitoring of measurable residual disease (MRD) should be implemented. Patients with AMKL might benefit from induced remission chemotherapy combined with novel targeted therapy. Hematopoietic stem cell transplantation should be carried out as soon as possible after the first CR induced by standard chemotherapy to optimize the prognosis.
Keywords: Acute megakaryocytic leukemia, proto-megakaryocyte, differential diagnosis, Clinical features, prognosis
Received: 10 Feb 2025; Accepted: 13 May 2025.
Copyright: © 2025 Liu, Liu, Chen, Yin, Xu, Xie, Shen, Huang and Dong Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hui Dong Guo, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.